Legend Total Revenue vs Total Current Assets Analysis
LEGN Stock | USD 48.29 5.76 10.66% |
Legend Biotech financial indicator trend analysis is infinitely more than just investigating Legend Biotech Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Legend Biotech Corp is a good investment. Please check the relationship between Legend Biotech Total Revenue and its Total Current Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Total Revenue vs Total Current Assets
Total Revenue vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Legend Biotech Corp Total Revenue account and Total Current Assets. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Legend Biotech's Total Revenue and Total Current Assets is 0.81. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Legend Biotech Corp, assuming nothing else is changed. The correlation between historical values of Legend Biotech's Total Revenue and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Legend Biotech Corp are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Revenue i.e., Legend Biotech's Total Revenue and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Revenue
Total revenue comprises all receipts Legend Biotech Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Legend Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Legend Biotech Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. As of the 7th of September 2024, Selling General Administrative is likely to grow to about 112.1 M, while Tax Provision is likely to drop about 268.9 K.
Legend Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Legend Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Legend Biotech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 938.8M | |
Short Long Term Debt Total | 6.1M | 3.4M | 123.0M | 284.5M | 328.7M | 345.1M | |
Other Current Liab | 70.9M | 99.2M | 211.4M | 260.9M | 140.1M | 143.2M | |
Total Current Liabilities | 127.8M | 161.2M | 280.3M | 297.8M | 216.4M | 203.5M | |
Total Stockholder Equity | (122.9M) | 280.3M | 471.2M | 744.3M | 1.3B | 1.3B | |
Other Liab | 277.8M | 277.7M | 244.8M | 7.9M | 7.1M | 6.7M | |
Net Tangible Assets | (123.4M) | 277.4M | 466.5M | 740.9M | 852.0M | 894.6M | |
Property Plant And Equipment Net | 75.5M | 121.3M | 155.1M | 161.7M | 189.7M | 116.2M | |
Current Deferred Revenue | 46.3M | 55.3M | 60.9M | 451K | 53.0M | 45.0M | |
Net Debt | (77.3M) | (452.3M) | (566.0M) | (501.5M) | (949.4M) | (901.9M) | |
Retained Earnings | (127.3M) | (430.8M) | (817.0M) | (966.5M) | (1.5B) | (1.4B) | |
Accounts Payable | 9.6M | 5.2M | 7.0M | 32.9M | 20.2M | 13.6M | |
Cash | 83.4M | 455.7M | 688.9M | 786.0M | 1.3B | 1.3B | |
Non Current Assets Total | 80.6M | 128.1M | 169.6M | 231.8M | 350.8M | 368.4M | |
Non Currrent Assets Other | 665K | 4.0M | 5.1M | 66.8M | 152.4M | 160.0M | |
Other Assets | 70.2M | 665K | 4.2M | 7.3M | 67.7M | 0.95 | |
Cash And Short Term Investments | 158.9M | 505.7M | 882.4M | 1.0B | 1.3B | 1.4B | |
Net Receivables | 35.8M | 85.0M | 63.2M | 90K | 157.1M | 164.9M | |
Liabilities And Stockholders Equity | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 938.8M | |
Non Current Liabilities Total | 282.8M | 279.6M | 366.9M | 288.9M | 373.5M | 318.6M | |
Inventory | 1.2M | 1.8M | 1.7M | 10.4M | 19.4M | 20.4M | |
Other Current Assets | 11.3M | 580.7M | 1.4M | 1.1B | 12.2M | 11.6M | |
Other Stockholder Equity | 3.9M | 430.8M | 817.0M | 744.3M | 2.6B | 2.8B | |
Total Liab | 410.6M | 440.8M | 647.2M | 586.7M | 589.9M | 522.0M | |
Total Current Assets | 207.1M | 592.9M | 948.8M | 1.1B | 1.5B | 770.5M | |
Accumulated Other Comprehensive Income | (122.9M) | 280.2M | 471.2M | 744.3M | 98.9M | 94.0M | |
Short Term Debt | 1.0M | 1.5M | 911K | 3.6M | 3.2M | 1.7M | |
Intangible Assets | 5.1M | 7.7M | 4.7M | 3.4M | 155.3M | 163.0M | |
Property Plant Equipment | 79.4M | 121.1M | 152.9M | 160.8M | 184.9M | 100.7M | |
Short Term Investments | 75.6M | 50M | 193.5M | 239.6M | 31.0M | 29.5M | |
Capital Lease Obligations | 6.1M | 3.4M | 2.5M | 23.6M | 47.3M | 49.7M | |
Net Invested Capital | (122.9M) | 280.3M | 591.7M | 1.0B | 1.5B | 1.6B | |
Property Plant And Equipment Gross | 74.8M | 116.5M | 155.1M | 161.7M | 224.7M | 140.2M | |
Net Working Capital | 79.3M | 431.7M | 668.5M | 801.3M | 1.3B | 1.3B |
Pair Trading with Legend Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Legend Stock
0.86 | PHIO | Phio Pharmaceuticals Corp | PairCorr |
0.81 | RNAZ | Transcode Therapeutics | PairCorr |
0.8 | PCRX | Pacira Pharmaceuticals | PairCorr |
0.76 | AKAN | Akanda Corp | PairCorr |
0.74 | PALI | Palisade Bio | PairCorr |
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Legend Stock
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 2.505 | Quarterly Revenue Growth 1.544 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.